About this Research Topic
Pulmonary arterial hypertension (PAH) is a severe arteriopathy characterized by progressive pulmonary vascular remodeling and increased pulmonary vascular resistance leading to right heart failure and often resulting in death. It remains a life-threatening disease with a high mortality rate. Its early diagnosis and treatment are of great significance to reduce mortality and limit adverse events. The clinical symptoms of PAH vary among individuals, and different cases often present with different combinations of symptoms. Right heart catheterization is considered the "gold standard" for diagnosing PAH. Unfortunately, due to the complex etiology, there are no serological markers for the diagnosis of PAH. Drugs targeting the nitric oxide pathway, endothelin pathway and prostaglandin pathway are developed to treat PAH, but despite these treatments, the mortality rate remains high as the condition often proves non-reversible.
Extensive research has been conducted to understand the pathogenesis of PAH and identify potential therapeutic targets. Various emerging molecules are being explored for their potential use in early diagnosis. Newer targets expressed in the pathobiology of PAH and newer formulation strategies for these targets are currently being potential treatment options.
This Research Topic aims to investigate the function and structure of the pulmonary artery and the right heart system, with a specific focus on the pulmonary artery-right heart coupling. We’d like to provide an overview on the current epidemiological characteristics of PAH, the latest progress in its pathophysiology and pathogenesis updates on treatment strategies, novel treatment methods and available evidence-based medicine evidence.
We welcome submissions on the following topics, but not limited to:
- Epidemiological and genetic characteristics of PAH in different regions.
- Progress and new ideas on the pathogenesis of PAH.
- Epigenetic Mechanisms in PAH.
- Emerging molecules for the diagnosis of PAH.
- Role of metabolic remodeling and mitochondrial dysfunction in PAH.
- Novel targets and emerging therapeutic modalities in PAH.
- Treatment strategies and prognosis of patients with different subtypes of PAH
Extensive research has been conducted to understand the pathogenesis of PAH and identify potential therapeutic targets. Various emerging molecules are being explored for their potential use in early diagnosis. Newer targets expressed in the pathobiology of PAH and newer formulation strategies for these targets are currently being potential treatment options.
This Research Topic aims to investigate the function and structure of the pulmonary artery and the right heart system, with a specific focus on the pulmonary artery-right heart coupling. We’d like to provide an overview on the current epidemiological characteristics of PAH, the latest progress in its pathophysiology and pathogenesis updates on treatment strategies, novel treatment methods and available evidence-based medicine evidence.
We welcome submissions on the following topics, but not limited to:
- Epidemiological and genetic characteristics of PAH in different regions.
- Progress and new ideas on the pathogenesis of PAH.
- Epigenetic Mechanisms in PAH.
- Emerging molecules for the diagnosis of PAH.
- Role of metabolic remodeling and mitochondrial dysfunction in PAH.
- Novel targets and emerging therapeutic modalities in PAH.
- Treatment strategies and prognosis of patients with different subtypes of PAH
Keywords: emerging molecules, pulmonary arterial hypertension
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
